Biochemical pharmacology of serotonin receptor subtypes: hypotheses for clinical applications of selective serotonin ligands

References

• Amsterdam J.D. Gepirone, a selective serotonin (5-HTIA) partial agonist in the treatment of major depression. Progress in Neuropsychopharmacology and Biological Psychiatry 1992; 16: 271–280
   Google Scholar
• Ballenger J.C., Goodwin F.K., Major L.F., Brown G.L. Alcohol and central serotonin metabolism in man. Archives of General Psychiatry 1979; 36: 224–227
   PubMed Web of Science ®Google Scholar
• Barnes J.M., Barnes N.M., Costall B., Naylor R.J., Tyers M.B. 5-HT3 receptors mediate inhibition of acetylcholine release in cortical tissue. Nature 1989; 338: 762–763
   PubMed Web of Science ®Google Scholar
• Barnes J.M., Costall B., Coughlan J., Domeney A.M., Gerrard P.A., Kelly M.E., Naylor R.J., Onaivi E.S., Tomkins D.M., Tyers M.B. The effects of ondansetron, a 5-HT3 receptor antagonist, on cognition in rodents and primates. Pharmacology, Biochemistry, & Behavior 1990; 35: 955–962
   PubMed Web of Science ®Google Scholar
• Bersani G., Grispini A., Marini S., Pasini A., Valducci M., Ciani N. 5-HT2 antagonist ritanserin in neurolepric-induced Parkinsonism: a double-blind comparison with orphenadrine and placebo. Clinical Neuropharmacology 1990; 13: 500–506
   PubMedGoogle Scholar
• Bielenberg G.W., Burkhardt M. 5-hydroxytryptaminei A agonists: a new therapeutic principle for stroke treatment. Stroke 1990; 21(suppl. 4)161–163
   Google Scholar
• Blackburn T.P. 5-HT receptors and anxiolytic drugs. Central Serotonin Receptors and Psychotropic Drugs, C.A. Marsden, D.J. Heal. Blackwell Scientific, London 1992; 175–197
   Google Scholar
• Blundell J.E. Is there a role for serotonin (5-hydroxytryptamine) in feeding?. International Journal of Obesity 1977; 1: 15–42
   PubMed Web of Science ®Google Scholar
• Bockaert J., Ansanay H., Waeber C., Sebben M., Fagni L., Dumuis A. 5-HT4 Receptors. Potential therapeutic implications in neurology and psychiatry. CNS Drugs 1994; 1: 6–15
   Google Scholar
• Bockaert J., Fozard J., Dumuis A., Clarke D.E. The 5-HT4 receptor a place in the sun. Trends in Pharmacological Sciences 1992; 13: 141–145
   PubMed Web of Science ®Google Scholar
• Brewerton T.D., Murphy D.L., Jimerson D.C. Testmeal responses following m-chlorophenylpiperazine and L-tryptophan in bulimics and controls. Neuropsychopharmacology 1994; 11: 63–71
   PubMed Web of Science ®Google Scholar
• Briley M., Chopin P. Serotonin in anxiety: evidence from animal models. 5-Hydroxytryptamine m Psychiatry: a spectrum of ideas, M. Sandler, A. Coppen, S. Harnett. Oxford University Press, Oxford 1991; 177–197
   Google Scholar
• Brown S.-L., Bleich A., Van Praag H.M. The monoamine hypothesis of depression: the case for serotonin. The Role of Serotonin in Psychiatric Disorders, S.-L. Brown, H.M. Van Praag. Brunner/Mazel, New York 1991; 91–128
   Google Scholar
• Bruno F. Buspirone in the treatment of alcoholic patients. Psychopathology 1989; 22(suppl. 1)49–59
   Google Scholar
• Bunce K., Tyers M., Beranek P. Clinical evaluation of 5-HT3 receptor antagonists as anti-emetics. Trends in Pharmacological Sciences 1991; 12: 46–48
   PubMed Web of Science ®Google Scholar
• Chopin P., Briley M. Animal models of anxiety: the effect of components that modify 5-HT neurotransmission. Trends in Pharmacological Sciences 1987; 8: 383–388
   Web of Science ®Google Scholar
• Coccaro E.F. Central serotonin and impulsive aggression. British Journal of Psychiatry 1989; 155(suppl. 8)52–62
   Google Scholar
• Collins D.M., Myers R.D. Buspirone attenuates volitional alcohol intake in the chronically drinking monkey. Alcohol 1987; 4: 49–56
   PubMed Web of Science ®Google Scholar
• Collingridge G.L., Singer W. Excitatory amino acid receptors and synaptic plasticity. Trends in Pharmacological Sciences 1990; 11: 290–296
   PubMed Web of Science ®Google Scholar
• Conn P.J., Sanders-Bush E. Central serotonin receptors: effector systems, physiological roles and regulation. Psychopharmacology 1987; 92: 267–277
   PubMed Web of Science ®Google Scholar
• Costall B., Naylor R.J. 5-HT receptors and antipsychotic drugs. Central Serotonin Receptors and Psychotropic Drugs, C.A. Marsden, D.J. Heal. Blackwell Scientific, London 1992; 198–221
   Google Scholar
• Costall B., Naylor R.J., Tyers M.B. The psychopharmacology of 5-HT3 receptors. Pharmacology and Therapeutics 1990; 47: 181–202
   PubMed Web of Science ®Google Scholar
• Cowen P.J. Serotonin receptor subtypes: implication for psychopharmacology. British Journal of Psychiatry 1991; 159(suppl. 12)7–14
   PubMedGoogle Scholar
• Crisp A.H., Lacey J.H., Crutchfield M. Clomipramine and ‘drive’ in people with anorexia nervosa. British Journal of Psychiatry 1987; 50: 355–358
   Google Scholar
• Curzon G., Kennett G.A., Whitton P. Anxiogenic effect of the 5-HTIC agonist m-chlorophenylpiperazine. 5-Hydroxytryptamine in Psychiatry: A Spectrum of Ideas, M. Sandler, A. Coppen, S. Harnett. Oxford University Press, Oxford 1991; 198–206
   Google Scholar
• De Koning P., Allsopp L.F., Van Den Broeck P., Mak M. Eltoprazine (5-HT1-agonist): early clinical results in patients with aggressive behavior. Biological Psychiatry 1991; 29(11, suppl.)210S
   Google Scholar
• De Vries M.H., De Koning P., Floot H.L., Grahnen A., Eckernas S.A., Raghoebar M., Dahlstrom B., Ekman L. Dose-proportionality of eltoprazine: pharmacokinetics of single oral doses in healthy subjects. European Journal of Clinical Pharmacology 1991; 41: 485–488
   PubMed Web of Science ®Google Scholar
• Dourish C.T., Cooper S.J., Gilbert F., Coughlan J., Iversen S.D. The 5-HTIA agonist 8-OH-DPAT increases consumption of the palatable wet mash and liquid diets in the rat. Psychopharmacology 1988; 94: 58–63
   Google Scholar
• Dubovsky S.L. Beyond the serotonin reuptake inhibitors: rationales for the development of new serotonergic agents. Journal of Clinical Psychiatry 1994; 55(suppl. 2)34–44
   PubMedGoogle Scholar
• Engel J.A., Fahlke C., Hard E., Johannessen K., Svensson L., Soderpalm P. Serotonergic and dopaminergic involvement in ethanol intake. Clinical Neuropharmacology 1992; 15(suppl. 1)64A–65A
   Google Scholar
• Fadda F., Garau B., Marchei F., Colombo G., Gessa G.L. MDL 72222, a selective 5-HT3 receptor antagonist, suppresses voluntary ethanol consumption in alcohol-preferring rats. Alcohol, & Alcoholism 1991; 26: 107–110
   PubMedGoogle Scholar
• Fozard J.R. Pharmacological relevance of 5-HT3 receptors. Serotonin receptor subtypes: pharmacological significance and clinical implications, International Academy for Biomedical and Drug Research, S.Z. Langer, N. Brunello, G. Racagni, J. Mendlewicz. Karger, Basel 1992; 44–55
   Google Scholar
• Glitz D.A., Pohl R. 5-HTIA partial agonists: what is their future?. Drugs 1991; 41: 11–18
   PubMed Web of Science ®Google Scholar
• Golden R.N., Gilmore J.H., Corrigan M.H.N., Ekstrom R.D., Knight B.T., Garbutt J.C. Serotonin, suicide, and aggression: clinical studies. Journal of Clinical Psychiatry 1991; 52(suppl. 12)61–69
   PubMedGoogle Scholar
• Gorelick D.A. Serotonin uptake blockers and the treatment of alcoholism. Recent Developments in Alcoholism, M. Galanter. Plenum Press, New York 1989; 7: 267–281
   Google Scholar
• Grossman C.J., Kilpatrick G.J., Bunce K.T. Development of a radioligand binding assay for 5-HT4 receptors in guinea pig and rat brain. British Journal of Pharmacology 1993; 109: 618–624
   PubMed Web of Science ®Google Scholar
• Gwirtsmann H.E., Guze B.H., Yager J., Gainsley B. Fluoxetine treatment of anorexia nervosa: an open clinical trial. Journal of Clinical Psychiatry 1990; 51: 378–382
   Google Scholar
• Hagan R.M., Jones B.J., Jordan C.C., Tyers M.B. Effect of 5-HT3 receptor antagonists on responses to selective activation of mesolimbic dopaminergic pathways in the rat. British Journal of Pharmacology 1990; 99: 227–232
   Google Scholar
• Harrington M.A., Zhong P., Garlow S.J., Ciaranello R.D. Molecular biology of serotonin receptors. Journal of Clinical Psychiatry 1992; 53(suppl. 10)8–27
   Google Scholar
• Hilleman D.E. Effect of buspirone on withdrawal symptoms associated with smoking cessation. Archives of Internal Medicine 1992; 152: 350–352
   PubMedGoogle Scholar
• Hilleman D.E., Mohiuddin S.M., Delcore M.G. Comparison of fixed-dose transdermal nicotine, tapered-dose transdermal nicotine, and buspirone in smoking cessation. Journal of Clinical Pharmacology 1994; 34: 222–224
   Google Scholar
• Hoyer D., Middlemiss D.N. Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain. Trends in Pharmacological Sciences 1989; 10: 130–132
   PubMed Web of Science ®Google Scholar
• Hover D., Schoeffter P., Waeber C., Palcios J.M. Serotonin 5-HTID receptors. Annals of the New York Academy of Sciences 1990; 60: 168–181
   Google Scholar
• Idzikowski C., Mills F.J., James R.J. A dose-response study examining the effects of ritanserin on human slow wave sleep. British Journal of Clinical Pharmacology 1991; 31: 193–196
   Google Scholar
• Julius D., MacDermott A.B., Axel R., Jessel T.M. Molecular characterization of a functional cDNA encoding the serotoninIC receptor. Science 1988; 241: 558–564
   PubMed Web of Science ®Google Scholar
• Kaye W.H., Weltzin T.E. Serotonin activity in anorexia and bulimia nervosa: relationship to the modulation of feeding behavior. Journal of Clinical Psychiatry 1991; 52(suppl. 12)41–48
   Google Scholar
• Kaye W.H., Weltzin T.E., Hsu L.K.G., Bulik C.M. An open trial of fluoxetine in patients with anorexia nervosa. Journal of Clinical Psychiatry 1991; 52: 464–471
   PubMed Web of Science ®Google Scholar
• Kennett G.A., Curzon G. Potencies of antagonists indicate that 5-HTIC receptors mediate 1–3(chlorophenyl)-piperazine-induced hypophagia. British Journal of Pharmacology 1991; 103: 2016–2020
   Google Scholar
• Knapp D.J., Benjamin D., Pohorecky L.A. Effects of gepirone on ethanol consumption, exploratory behavior, and motor performance in rats. Drug Development and Research 1992; 26: 319–341
   Web of Science ®Google Scholar
• Kohen D. Eltoprazine for aggression in mental handicap. Lancet 1993; 341: 628–629
   Google Scholar
• Kostowski W., Dyr W. Effects of the 5-HTIA receptor agonists on ethanol preference in the rat. Alcohol 1992; 9: 283–286
   PubMed Web of Science ®Google Scholar
• Kranzler H.R., Burleson J.A., Del Boca F.K., Babor T.F., Korner P., Brown J., Bohn M.J. Buspirone treatment of anxious alcoholics. Archives of General Psychiatry 1994; 51: 720–731
   PubMed Web of Science ®Google Scholar
• Kranzler H.R., Meyer R.E. An open trial of buspirone in alcoholics. Journal of Clinical Psychopharmacology 1989; 9: 379–380
   PubMed Web of Science ®Google Scholar
• Krawttz H.M., Fawcett J. Serenics for aggressive behaviors. Psychiatric Annals 1994; 24: 453–459
   Google Scholar
• Lecrubier Y., Puech A.J., Azcona A. (1990) 5-HT3 receptors in anxiety disorders. Proceedings of the British Association of Psychopharmacology Annual Meeting, CambridgeUK, July, 1990, Abs. 19
   Google Scholar
• Lemarquand D., Pihl R.O., Benkelfat C. Serotonin and alcohol intake, abuse, and dependence: clinical evidence. Biological Psychiatry 1994; 36: 326–337
   PubMed Web of Science ®Google Scholar
• Leysen J.E. 5-HT2-receptors: location, pharmacological, pathological and physiological role. Serotonin receptor subtypes: pharmacological significance and clinical implications, International Academy for Biomedical and Drug Research, S.Z. Langer, N. Brunello, G. Racagni, J. Mendlewicz. Karger, Basel 1992; 31–43
   Google Scholar
• Leysen J.E., Pauwels P. 5-HT2 receptors, roles and regulation. The neuropharmacology of serotonin. Annals of the Nezo York Academy of Sciences 1990; 600: 183–193
   Google Scholar
• Lucki I. Behavioral studies of serotonin receptor agonists as antidepressant drugs. Journal of Clinical Psychiatry 1991; 52(suppl. 12)24–31
   Google Scholar
• Mak M., De Koning P., Van Den Broek P. Eltoprazine in aggressive psychotic and personality disordered patients. Clinical Neuropharmacology 1992; 15(suppl. 1)373B, pt. B
   Google Scholar
• Marsden C.A., Kendall D.A. Neurochemical identification of 5-HT receptor subtypes. Central Serotonin Receptors and Psychotropic Drugs, C.A. Marsden, D.J. Heal. Blackwell Scientific, London 1992; 17–38
   Google Scholar
• McGrath P.J., Stewart J.W., Quttkin F.M., Wager S., Jenkins S.W., Archibald D.G., Stringfellow J.C., Robinson D.S. Gepirone treatment of atypical depression: preliminary evidence of serotonergic involvement. Journal of Clinical Psychopharmacology 1994; 14: 347–352
   Google Scholar
• Meert T.F., Awouters F., Niemegeers C.J.E., Schellekens K.H.L., Janssen P.A.J. Ritanserin reduces abuse of alcohol, cocaine and fentanyl in rats. Pharmacopsychiatry 1991; 24: 159–163
   Google Scholar
• Meltzer H. The importance of serotonin-dopamine interactions in the action of clozapine. British Journal of Psychiatry 1992; 160(suppl. 17)22–29
   Google Scholar
• Mesotten F., Suy E., Pietquin M., Burton P., Heylen S., Gelders Y. Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients. Psychopharmacology 1989; 99: 445–449
   PubMed Web of Science ®Google Scholar
• Molineaux S.M., Jessell T.M., Axel R., Julius D. The 5-HTIC receptor is a prominent serotonin receptor subtype in the central nervous system. Proceedings of the National Academy of Sciences of the USA 1989; 86: 6793–6797
   PubMed Web of Science ®Google Scholar
• Monferini E., Gaetani P., Rodriguez y Baena R., Giraldo E., Parenti M., Zocchetti A., Rizzi C.A. Pharmacological characterization of die 5-hydroxytryptamine receptor coupled to adenylyl cyclase stimulation in human brain. Life Sciences 1993; 52: 61–65
   Google Scholar
• Montgomery A.M.J., Rose I.C., Herberg L.J. 5-HTIA agonists and dopamine: the effects of 8-OH-DPAT and buspirone on brain-stimulation reward. Journal of Neural Transmission, General Section 1991; 83: 139–148
   Web of Science ®Google Scholar
• Mos J., Olivier B., Tulp M ThM. Ethopharmacological studies differentiate the effects of various serotonergic compounds on aggression in rats. Drug Development Research 1992; 26: 343–360
   Google Scholar
• Olivier B., Mos J. Serotonin receptor subtypes and aggressive behavior. Neuropsychopharmacology 1994; 10(3S, part 1)944S
   Google Scholar
• Olivier B., Van Dalen D., Hartog J. A new class of psychotroptic drugs: serenics. Drugs Future 1986; 11: 473–494
   Google Scholar
• Palacios J.M., Waeber C., Mengod G., Pompeiano M. Molecular neuroanatomy of 5-HT receptors. Serotonin: Molecular Biology, Receptors and Functional Effects, J.R. Fozard, P.R. Saxena. Birkhauser, Basel 1991; 5–20
   Google Scholar
• Paris J.M., Cunningham K.A. Serotonin 5-HT3 antagonists, do not alter the discriminative stimulus properties of cocaine. Psychopharmacology 1991; 104: 475–478
   Google Scholar
• Pazos A., Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain, I: serotonin-1 receptors. Brain Research 1985; 346: 205–230
   PubMed Web of Science ®Google Scholar
• Pearce J.M.S. Sumatriptan: efficacy and contribution to migraine mechanisms (editorial). Journal of Neurology, Neurosurgery and Psychiatry 1992; 55: 1103–1105
   PubMed Web of Science ®Google Scholar
• Peltier R., Schenk S. GR38032F, a serotonin 5-HT3 antagonist, fails to alter cocaine self-administration in rats. Pharmacology, Biochemistry and Behavior 1991; 39: 133–136
   PubMed Web of Science ®Google Scholar
• Peroutka S.J. 5-Hydroxytryptamine receptors. Journal of Neurochemistry 1993; 60: 408–416
   PubMed Web of Science ®Google Scholar
• Peroutka S.J., Sleight A.J. Central serotonin receptors: functional correlates and clinical relevance. The Role of Serotonin in Psychiatric Disorders, S.-L. Brown, H.M. Van Praag. Brunner/Mazel, New York 1991; 8–26
   Google Scholar
• Privette T.H., Hornsby R.I., Myers R.D. Buspirone alters alcohol drinking induced in rats by tetrahydropapaveroline injected into brain monoaminergic pathways. Alcohol 1988; 5: 147–152
   Google Scholar
• Radja F., Laporte A.-M., Daval G., Vergé D., Gozlan H., Hamon M. Autoradiography of serotonin receptor subtypes in the central nervous system. Neurochemistry International 1991; 18: 1–15
   Google Scholar
• Ratey J.J., Gordon A. The psychopharmacology of aggression: toward a new day. Psychopharmacology Bulletin 1993; 29: 65–73
   PubMedGoogle Scholar
• Robinson D.S., Rickels K., Feighner J., Fabre L. F., Jr., Gammans R.E., Shrotriya R.C., Alms D.R., Andry J.J., Messina M.E. Clinical effects of the 5-HTIA partial agonists in depression: a composite analysis of buspirone in the treatment of depression. Journal of Clinical Psychopharmacology 1990; 10(suppl 3)67S–76S
   Google Scholar
• Roy A., Virkkunen M., Linnoila M. Serotonin in suicide, violence, and alcoholism. Serotonin in Major Psychiatric Disorders, E.F. Coccaro, D.L. Murphy. American Psychiatric Press, Washington, DC 1990
   Google Scholar
• Saller C.F., Czupryna M.J., Salama A.I. 5-HT2 receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade. Journal of Pharmacology, & Experimental Therapeutics 1990; 253: 1162–1170
   Google Scholar
• Sellers E.M., Higgins G.A., Tomkins D.M., Romach M.K., Toneatto T. Opportunities for the treatment of psychoactive substance use disorders with serotonergic medications. Journal of Clinical Psychiatry 1991; 52: 49–54, suppl
   PubMed Web of Science ®Google Scholar
• Stahl S.M. New therapeutic advances in schizophrenia. Schizophrenia: Exploring the Spectrum of Psychosis, R.J. Ancill, S. Holliday, J. Higenbottam. John Wiley, Chichester 1994; 137–152
   Google Scholar
• Svensson L., Fahlke C., Hard E., Engel J.A. Involvement of the serotonergic system in ethanol intake in the rat. Alcohol 1993; 10: 219–224
   PubMed Web of Science ®Google Scholar
• Tihonen J., Hakola P., Paanila J., Turtiainen M. Eltoprazine for aggression in schizophrenia and mental retardation. Lancet 1993; 341: 307
   Google Scholar
• Tips. Receptor and Ion Channel Nomenclature Supplement. Trends in Pharmacological Sciences. 1994
   Google Scholar
• Tollefson G.D., Lancaster S.P., Montague-Clouse J. The association of buspirone and its metabolite 1-pyrimidinylpiperazine in the remission of comorbid anxiety with depressive features and alcohol dependency. Psychopharmacology Bulletin 1991; 27: 163–170
   PubMedGoogle Scholar
• Tricklebank M.D. Interactions between dopamine and 5-HT3 receptors suggest new treatments for psychosis and drug addiction. Trends in Pharmacological Sciences 1989; 10: 127–129
   PubMedGoogle Scholar
• Tyrer S.P., Moore P.B. Eltoprazine improves autistic symptoms in self-injurious mentally handicapped patients. European Neuropsychopharmacology 1993; 3: 384
   Google Scholar
• Verhoeven W.M.A., Tuinier S., Sijben N.A.S., Van Den Berg Y.W., De Witte-Van Der Schoot E.P., Pepplinkhuizen L., Van Nieuwenhuizen O. Eltoprazine in mentally retarded self-injuring patients. Lancet 1992; 340: 1037–1038
   PubMed Web of Science ®Google Scholar
• Waeber C., Hoyer D., Palacios J.M. 5-HT3 receptors in the human brain: autoradiographic visualization. Neuroscience 1989; 31: 393–400
   Google Scholar
• Waeber C., Schoeffter P., Hoyer D., Palacios J.M. The serotonin 5-HTID receptor: a progress review. Neurochemical Research 1990; 15: 567–582
   Google Scholar
• Waeber C., Sebben M., Grossman C., Javoy-Agid F., Bockaert J., Dumuis A. [3H]-GR 113808 labels 5-HT4 receptors in the human and guinea pig brain. Neuroreport 1993; 4: 1239–1242
   PubMedGoogle Scholar
• Walsh A.E.S., Smith K.A., Oldman A.D., Williams C., Goodall E.M., Cowen P.J. m-chlorophenylpiperazine decreases food intake in a test meal. Psychopharmacology 1994; 116: 120–122
   PubMed Web of Science ®Google Scholar
• Watling K.J., Beer M.S., Stanton J.S. Effect of clozapine and other neuroleptics on binding of [3H]-QICS 205–930 to central 5-HT3 recognition sites. British Journal of Pharmacology 1989; 98: 813P
   Google Scholar